{
    "company_name": "HEXIMA LIMITED.",
    "address": "C/-Acclime, Level 3, 62 Lygon Street, CARLTON, VIC, AUSTRALIA, 3053",
    "summary": "Research and development of plant-derived proteins and peptides for applications as human therapeutics.",
    "details": "Research and development of plant-derived proteins and peptides for applications as human therapeutics.",
    "website": "https://hexima.com.au/",
    "stock_code": "HXL",
    "links": "['https://hexima.com.au', 'https://hexima.com.au/about-us/', 'https://hexima.com.au/about-us/', 'https://hexima.com.au/about-us/leadership-advisory/', 'https://hexima.com.au/about-us/latest-news/', 'https://hexima.com.au/contact-hexima/', 'https://hexima.com.au/our-technology/', 'https://hexima.com.au/our-technology/', 'https://hexima.com.au/literature/', '/pezadeftide', 'https://hexima.com.au/pezadeftide/', 'https://hexima.com.au/onychomycosis/', 'https://hexima.com.au/kol-interviews/', 'https://hexima.com.au/about-us/latest-news/', 'https://hexima.com.au/investor-centre/', 'https://hexima.com.au/investor-centre/', 'https://hexima.com.au/investor-centre/corporate-governance/', 'https://hexima.com.au/investor-centre/asx-announcements/', 'https://hexima.com.au/investor-centre/reports/', 'https://hexima.com.au/investor-centre/investor-services/', 'https://hexima.com.au/', 'https://hexima.com.au/about-us/', 'https://hexima.com.au/about-us/', 'https://hexima.com.au/about-us/leadership-advisory/', 'https://hexima.com.au/about-us/latest-news/', 'https://hexima.com.au/contact-hexima/', 'https://hexima.com.au/our-technology/', 'https://hexima.com.au/our-technology/', 'https://hexima.com.au/literature/', '/pezadeftide', 'https://hexima.com.au/pezadeftide/', 'https://hexima.com.au/onychomycosis/', 'https://hexima.com.au/kol-interviews/', 'https://hexima.com.au/about-us/latest-news/', 'https://hexima.com.au/investor-centre/', 'https://hexima.com.au/investor-centre/', 'https://hexima.com.au/investor-centre/corporate-governance/', 'https://hexima.com.au/investor-centre/asx-announcements/', 'https://hexima.com.au/investor-centre/reports/', 'https://hexima.com.au/investor-centre/investor-services/', '#', '/project/hxp124/', '/onychomycosis/', '/our-technology/', '/kol-interviews/', 'https://www.linkedin.com/company/hexima-limited/', 'https://twitter.com/HeximaLimited', 'https://hexima.com.au/investor-centre/investor-services#email-alerts', '#', 'https://hexima.com.au/wp-content/uploads/2020/10/ABL-8270850-1-Hexima-Limited-Privacy-Policy.pdf']",
    "images": "https://hexima.com.au/wp-content/uploads/2015/06/hexima-logo.png, https://hexima.com.au/wp-content/uploads/2015/06/hexima-logo.png, https://hexima.com.au/wp-content/uploads/2022/02/Block2_Icon1_icons_500x500_WithColour-04.png, https://hexima.com.au/wp-content/uploads/2022/02/Block2_Icon2_Hexima_icons_500x500_WithColour-01.png, https://hexima.com.au/wp-content/uploads/2022/02/Block2_Icon3_Hexima_icons_500x500_WithColour-11.png, https://hexima.com.au/wp-content/uploads/2022/01/Pezadeftide_HD_03.00_01_12_02.Still011.jpg, https://hexima.com.au/wp-content/uploads/2022/01/Pezadeftide_HD_03.00_01_04_09.Still012.jpg, https://hexima.com.au/wp-content/uploads/2022/02/1_Header_Image_shutterstock_1694388448.jpg, https://hexima.com.au/wp-content/uploads/2022/02/WhiteLogo_Hexima.png",
    "company_logo_link": "https://hexima.com.au/wp-content/uploads/2015/06/hexima-logo.png"
}